Fenestrated endovascular aneurysm repair (FEVAR) has become an option to treat patients with complex abdominal aortic aneurysms (AAAs) not eligible for standard endovascular aneurysm repair (EVAR). [1] [2] [3] [4] Alternatively, open repair of juxtarenal, suprarenal, and type IV thoracoabdominal aneurysms may be associated with an increased risk of perioperative morbidity and mortality, particularly among unfit patients and octogenarians. 5, 6 According to Raval and Eskandari, 6 octogenarians with infrarenal aneurysms have lower early mortality rates after EVAR compared with open repair. For complex AAAs, Hertault et al 7 recently reported that FEVAR is a safe and effective alternative for octogenarians with juxtarenal aneurysms. Clinical outcomes of FEVAR for octogenarians with complex AAAs have not been established, particularly for aneurysmal disease extending above the renal arteries. The aim of this study was to evaluate perioperative and midterm outcomes of FEVAR among octogenarians with complex AAA at high and standard risk for open repair.
METHODS
Selection of patients. After Institutional Review Board (IRB) approval, a single-institutional, retrospective review of a prospectively maintained database for all patients who underwent FEVAR with premanufactured devices during a 33-month period was performed.
All patients in this series underwent FEVAR using Food and Drug Administration-approved Zenith (Cook timaran@utsouthwestern.edu).
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Copyright Medical, Bloomington, Ind) Fenestrated AAA Endovascular Graft (ZFEN), investigational custom-made devices (investigational device exemption G140108), or investigational off-the-shelf p-Branch fenestrated endograft (investigational device exemption G12013). When investigational devices were used, all patients signed an IRB-approved informed consent form to participate in research. For Food and Drug Administration-approved devices, data collection was performed under IRB-approved informed consent form waiver. Patients were organized in two groups; group 1 included patients 80 years and older, whereas patients younger than 80 years were included in group 2.
Demographics and comorbidities were evaluated for patients older than 80 years and younger patients. Indications for FEVAR included type IV thoracoabdominal, suprarenal, and juxtarenal aortic aneurysms; type Ia endoleaks after previous EVAR; and penetrating atherosclerotic ulcerations.
Aneurysm classification was based on the recommended reporting standards for aneurysm repair of the Society for Vascular Surgery (SVS). 8 A juxtarenal aortic aneurysm is defined as an aneurysm with <10 mm infrarenal aortic neck with involvement of the aneurysmal dilation up to the level of the renal arteries, which originate from normal aorta. Suprarenal aortic aneurysm involves the origin of at least one renal artery but does not extend into the celiac artery. Type IV thoracoabdominal aortic aneurysms involve the origin of all four visceral arteries, including the celiac axis, extending up to the diaphragmatic hiatus. Technical success was defined as successful delivery and deployment of the fenestrated device with preservation of those branch vessels intended to be preserved in the absence of type I (Ia and Ib) endoleak. Postoperative outcomes at 30 days were recorded. Postoperative events, mortality, and secondary intervention rates during the follow-up period were also analyzed. Major adverse events at 30 days were defined, as described by Greenberg et al, 9 as the presence of one of the following: all-cause mortality, bowel ischemia (requiring medical therapy or surgical therapy), myocardial infarction (raised levels of cardiac biomarkers or electrocardiographic changes), paraplegia, respiratory failure (pneumonia or respiratory failure requiring ventilator support for >24 hours), stroke, and renal failure requiring dialysis. Patients included in this study were divided in two groups, group 1 for patients older than 80 years and group 2 for younger patients.
Follow-up. Postoperative computed tomography angiography (with contrast-enhanced arterial and venous phases) was performed within the first month after the procedure for every patient when renal function was compatible with iodine contrast agent. If not, computed tomography without contrast enhancement was performed in association with duplex ultrasound. Complete clinical and imaging follow-up visits were scheduled at 6 months, at 1 year, and annually thereafter.
Statistical
analysis. Continuous variables are expressed as median with interquartile range (IQR) and categorical data as percentage. Comparisons between groups were made with nonparametric analysis for continuous variables and c 2 and Fisher tests for categorical variables. Life-table analysis according to the Kaplan-Meier method was conducted to estimate survival and freedom from secondary intervention rates, and differences were tested with log-rank test. A P value < .05 was considered significant. All statistical analysis was performed with SAS 9.4 software (SAS Institute, Cary, NC).
RESULTS
During the study period, 85 patients, 68 men and 17 women (78% vs 22%) with median age of 73 years (IQR, 68-79), underwent FEVAR with Zenith Fenestrated AAA Endovascular Graft, Zenith p-Branch, and custom-made devices for complex AAAs. The median age was 84 years (IQR, 81-86 years) for the octogenarian group and 71 years (IQR, 67-75) for younger patients. Sixty-six patients (78%) were available for follow-up beyond 30 days. The median follow-up time for the entire cohort was 12 months (IQR, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Table I ). When the SVS score was recalculated controlling by age, the SVS score was 2.5 (IQR, 2-4) for octogenarians and 3 (IQR, 2-4) for younger patients (P ¼ .47).
The median number of fenestrations was three. The Zenith Fenestrated AAA Endovascular Graft was used in 60 patients (70%), Zenith p-Branch in 6 patients (7%), and investigational custom-made devices in 19 patients (22% Recommendation The authors suggest that age alone should not be a contraindication to fenestrated endovascular aneurysm repair.
patients in both groups. Intraoperatively, technical success was 100% for patients of both groups. The median operative time for group 1 was 224 minutes (IQR, 160-272) vs 212 minutes (IQR, 177-281) for group 2 (P ¼ .59). The rate of adjuvant intraoperative procedures was similar for patients of both groups, 33% for group 1 vs 31% for group 2 (P > .5). Intraoperative information is presented in Table II .
The median hospital length of stay was 3.5 days (IQR, 2-5) for group 1 vs 4 (IQR, 2-5) for group 2 (P ¼ .87). Intensive care unit length of stay was 2 days for patients from both groups (IQR, 1-3 ). The rate of major adverse events was 11% for patients $80 years and 8% for patients younger than 80 years (P > .5). The rate of postoperative complications was 28% for group 1 and 36% for group 2 (P ¼ .5). None of the patients in this series required dialysis. No 30-day deaths occurred. Table III shows postoperative outcomes by age group. Early morbidity in octogenarians is presented in Table IV . The overall mortality rate was similar among patients $80 years and younger patients during the follow-up period, according to the Kaplan-Meier method (P ¼ .1; Fig 1) . The 20-month estimated survival rate was 75% in group 1 and 91% in group 2. None of the deaths in both groups were aneurysm related. The rate of reinterventions at 20 months was 10% for group 1 and 57% for group 2 (P ¼ .09; Fig 2) . Secondary interventions at 20 months are shown in Table V . Six mortality events were reported in our study, three in the octogenarian group and three in the younger group, as follows. In the octogenarian group, one patient died of an acute kidney injury secondary to a perforated gastric ulcer. A second patient died of pulmonary complications at an outside hospital; no detailed information was provided. A third patient died of a cerebral hemorrhage after an aneurysm rupture. In the younger group, one patient died of acute hypoxic respiratory failure after acute renal failure and shock. A second patient underwent a surgical repair of a hernia and succumbed after multiple postoperative complications. A third patient died of a congestive heart failure exacerbation.
DISCUSSION
This single-center, observational, retrospective study reveals that perioperative and midterm outcomes are similar for octogenarians and patients younger than 80 years. Octogenarians, however, were shown to have lower rates of reinterventions at 24 months.
Octogenarian patients with complex AAAs and thoracoabdominal aneurysms have been shown to be at higher risk of death and morbidity after open surgery. [10] [11] [12] Studies assessing early and midterm outcomes have reported a mortality rate higher than 30%. 12, 13 In octogenarians undergoing standard EVAR, Lange et al, 14 using the European Collaborators on Stent/graft Techniques for aortic Aneurysm Repair (EUROSTAR) registry data, reported a 30-day mortality of 5% in octogenarians vs 2% in younger patients. Similarly, at the long term, octogenarians had a higher mortality rate compared with younger patients, 7% vs 3%.
14 Two recent studies were performed to assess postoperative outcomes of endovascular repair in octogenarians with juxtarenal and suprarenal aneurysms. Each study used two different techniques, fenestrated repair and chimney/snorkel technique. In the fenestrated study, 7 the mortality rate was 9% in octogenarians vs 1.6% in younger patients. In the same study, the 2-year survival rate was 77.8% in octogenarians. 7 For the chimney/snorkel study, the 30-day mortality rate was 2.9% with a 12-month survival rate of 94% and 72.8% at 3 years. 15 Our study differs with the mortality rates reported by other authors for octogenarians after either open or endovascular repair using different techniques. In our study, no deaths occurred at 30 days in either age group. The comorbidities profile in our study was similar to that of the two previous studies that reported clinical outcomes of endovascular repair for juxtarenal and pararenal aneurysms. 7, 15 However, in our study, we included patients with type IV thoracoabdominal aneurysms; the early mortality rate was lower than the rates reported by Hertault et al and Silveira et al. At 20 months, survival was similar to the previous studies with a survival rate higher than 75%. Regarding perioperative morbidity, Hertault et al 7 and Silveira et al 15 reported a 30-day complication of 30% and 14%, respectively, with a rate of major complications of 15% and 5.7%, respectively. In our study, 28% of our patients had complications at 30 days. One patient with an access site seroma underwent a reintervention within 30 days. None of our patients required dialysis, died, or had severe neurologic complications. The premorbid profile of our octogenarians is similar to what both studies reported; >90% of the patients had American Society of Anesthesiologists scores of 3 or 4. Renal function impairment was similar to what Silveira et al 15 reported; about 30% of the patients had some degree of renal dysfunction. At 24 months, both previous studies reported survival rates higher than 70%. 7, 15 These findings are similar to our results. The survival rate at 20 months in the octogenarian group was 75%, with a reintervention-free survival of 90%.
The primary limitations of this study relate to the retrospective design and the small sample size, specifically the small number of octogenarian patients undergoing procedures for different types of aneurysms with a number of devices. Similarly, only data from 75% of the total population were available for midterm analysis. We consider that further studies with larger populations that include long-term information are required to determine durability and survival of octogenarians after fenestrated repair.
CONCLUSIONS
FEVAR is a safe and effective procedure for octogenarians at high and standard risk for open repair who are not eligible for standard EVAR. In fact, octogenarians had midterm outcomes similar to those of younger patients, with a lower rate of reinterventions at 20 months. 
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